The cytogenetics market was valued at $2.80 billion in 2023 and is estimated to reach $10.62 billion by 2035, exhibiting a CAGR of 11.7% from 2024 to 2035.
Cytogenetics is a branch of genetics focused on the study of chromosomes, the structures within cells that contain DNA. It involves analyzing the number, structure, and behavior of chromosomes to understand their role in heredity, disease, and biological function. Techniques in cytogenetics, such as karyotyping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), allow scientists to identify chromosomal abnormalities, such as deletions, duplications, translocations, and aneuploidies. These abnormalities are linked to various genetic disorders, cancers, and congenital conditions.
By examining the chromosomal makeup of cells, cytogenetics plays a crucial role in prenatal diagnosis, cancer research, genetic counseling, and personalized medicine. The field bridges classical genetics with modern molecular biology, offering insights into how changes at the chromosomal level can affect an individual's health and development, making it an essential tool in both clinical and research settings.
The major factors that drive the growth of cytogenetics market include the rise in prevalence of genetic disorders and cancer globally which fuels demand for cytogenetic testing and diagnostics. As genetic conditions such as Down syndrome, and various types of cancer become more prevalent, the need for accurate and early detection methods has grown significantly. Cytogenetic techniques, including karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarray analysis (CMA), are essential for identifying chromosomal abnormalities associated with these conditions, thereby driving market growth.
However, the high cost associated with cytogenetic technologies, including equipment, and specialized expertise can be prohibitive, particularly in low- and middle-income countries, limiting access to advanced diagnostic tools and limiting the market growth. In addition, the complexity of cytogenetic procedures requires skilled professionals and specialized training, which can be scarce in certain regions, further constraining market growth. On the other hand, increase in demand for personalized medicine, which relies heavily on advanced genetic testing to tailor treatments to individual patients' genetic profiles and high growth potential in emerging countries create an opportunity for market expansion.
Cytogenetics market is categorized into product, technique, application, end user, and region. On the basis of the product, it is segmented into consumable, instrument, and software & service. The consumables segment is further classified into testing kits and reagents, media, probes, and others. Media segment further includes serum media and others. On the basis of technique, the market is segmented into comparative genome hybridization, fluorescence in situ hybridization, karyotyping, and others.
The karyotyping segment further categorized into prenatal testing, cancer, and others. Prenatal testing segment categorized into consumable, instrument, and software & services. Cancer segment further categorized into consumables which includes testing kits and reagents and media. Others segment also categorized into consumables which includes testing kits and reagents and media.
On the basis of application, it is segmented into genetic disorders, cancer, personalized medicine, and others. On the basis of end user, the market is classified into clinical and research laboratory, pharmaceutical and biotechnology company, academic research institute, and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA).
The major companies profiled in the report include PAN-Biotech, Precipio, Inc., Applied Spectral Imaging, Capricorn Scientific, AddLife, and Thermo Fisher Scientific Inc. The key players operating in the market have adopted partnership, joint venture, collaboration, and agreement as their key strategy to expand their product portfolio. For instance, in January 2024, Barco and Applied Spectral Imaging (ASI), a world leader in advanced biomedical imaging with a comprehensive product portfolio for karyotyping, H&E, IHC and FISH imaging and analysis, announced a new commercial partnership to offer best-in-class digital solutions for pathology laboratories
Cytogenetics is a branch of genetics focused on the study of chromosomes, the structures within cells that contain DNA. It involves analyzing the number, structure, and behavior of chromosomes to understand their role in heredity, disease, and biological function. Techniques in cytogenetics, such as karyotyping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), allow scientists to identify chromosomal abnormalities, such as deletions, duplications, translocations, and aneuploidies. These abnormalities are linked to various genetic disorders, cancers, and congenital conditions.
By examining the chromosomal makeup of cells, cytogenetics plays a crucial role in prenatal diagnosis, cancer research, genetic counseling, and personalized medicine. The field bridges classical genetics with modern molecular biology, offering insights into how changes at the chromosomal level can affect an individual's health and development, making it an essential tool in both clinical and research settings.
The major factors that drive the growth of cytogenetics market include the rise in prevalence of genetic disorders and cancer globally which fuels demand for cytogenetic testing and diagnostics. As genetic conditions such as Down syndrome, and various types of cancer become more prevalent, the need for accurate and early detection methods has grown significantly. Cytogenetic techniques, including karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarray analysis (CMA), are essential for identifying chromosomal abnormalities associated with these conditions, thereby driving market growth.
However, the high cost associated with cytogenetic technologies, including equipment, and specialized expertise can be prohibitive, particularly in low- and middle-income countries, limiting access to advanced diagnostic tools and limiting the market growth. In addition, the complexity of cytogenetic procedures requires skilled professionals and specialized training, which can be scarce in certain regions, further constraining market growth. On the other hand, increase in demand for personalized medicine, which relies heavily on advanced genetic testing to tailor treatments to individual patients' genetic profiles and high growth potential in emerging countries create an opportunity for market expansion.
Cytogenetics market is categorized into product, technique, application, end user, and region. On the basis of the product, it is segmented into consumable, instrument, and software & service. The consumables segment is further classified into testing kits and reagents, media, probes, and others. Media segment further includes serum media and others. On the basis of technique, the market is segmented into comparative genome hybridization, fluorescence in situ hybridization, karyotyping, and others.
The karyotyping segment further categorized into prenatal testing, cancer, and others. Prenatal testing segment categorized into consumable, instrument, and software & services. Cancer segment further categorized into consumables which includes testing kits and reagents and media. Others segment also categorized into consumables which includes testing kits and reagents and media.
On the basis of application, it is segmented into genetic disorders, cancer, personalized medicine, and others. On the basis of end user, the market is classified into clinical and research laboratory, pharmaceutical and biotechnology company, academic research institute, and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA).
The major companies profiled in the report include PAN-Biotech, Precipio, Inc., Applied Spectral Imaging, Capricorn Scientific, AddLife, and Thermo Fisher Scientific Inc. The key players operating in the market have adopted partnership, joint venture, collaboration, and agreement as their key strategy to expand their product portfolio. For instance, in January 2024, Barco and Applied Spectral Imaging (ASI), a world leader in advanced biomedical imaging with a comprehensive product portfolio for karyotyping, H&E, IHC and FISH imaging and analysis, announced a new commercial partnership to offer best-in-class digital solutions for pathology laboratories
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cytogenetics market analysis from 2023 to 2035 to identify the prevailing cytogenetics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cytogenetics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cytogenetics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update* (with the purchase of an enterprise license)
- 5 additional Company Profiles, pre- or post-purchase, as a free update.
- Free Updated Version (once released) with the purchase of an enterprise user license.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By Product
- Consumable
- Type
- Testing kits
- Media
- Type
- Probes
- Others
- Instrument
- Software and service
By Technique
- Comparitive genome hybridization
- Fluorescence in situ hybridization
- Karyotyping
- Type
- Prenatal Testing
- Type
- Cancer
- Consumables
- Others
- Consumable
- Others
By Application
- Genetic disorder
- Cancer
- Personalized medicine
- Others
By End User
- Clinical and research laboratory
- Type
- Cancer Research
- Clinical Diagnostics Labs
- Others
- Pharmaceutical and biotechnology company
- Academic Research Institute
- Other
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa,
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- AddLife
- Applied Spectral Imaging
- PAN-Biotech
- Precipio, Inc.
- Capricorn Scientific
- Thermo Fisher Scientific Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CYTOGENETICS MARKET, BY PRODUCT
CHAPTER 5: CYTOGENETICS MARKET, BY TECHNIQUE
CHAPTER 6: CYTOGENETICS MARKET, BY APPLICATION
CHAPTER 7: CYTOGENETICS MARKET, BY END USER
CHAPTER 8: CYTOGENETICS MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- AddLife
- Applied Spectral Imaging
- PAN-Biotech
- Precipio, Inc.
- Capricorn Scientific
- Thermo Fisher Scientific Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
